← Russell 3000 cross-section

ANAB ANAPTYSBIO, INC

Trailing twelve months to 2026-03-31 · as filed 2026-05-12, not restated
Healthcare

Scale

Market cap
$1.7bn
Revenue TTM
$232m
Net income TTM
$-27m
Free cash flow
$4m
Composite score
54.8
Sector rank
#1730

Valuation

P / E
EV / EBITDA
34.4
EV / sales
6.1
FCF yield
0.26%
Earnings yield vs 10-yr
-6.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-11.5%
EBITDA margin
17.8%
ROE
-210.1%
ROIC
Revenue growth
107.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We plan to use our current year operating losses and NOL to offset taxable income from any revenue generated from operations, corporate collaborations, or dividends due to the Spin-off. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities Purchases of Equity Securities by the Issuer In March 2025, our board of directors approved a stock repurchase program to repurchase up to $75.0 million of shares of our outstanding common stock, par value $0.001 per share (the “2025 Repurchase Program”).ANAPTYSBIO, INC, 10-Q, period ended 2026-03-31, filed 2026-05-12

Read the full passage →